Piper Sandler Maintains Neutral on Quest Diagnostics, Raises Price Target to $150
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Westenberg maintains a Neutral rating on Quest Diagnostics (NYSE:DGX) and raises the price target from $145 to $150.

July 29, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler analyst David Westenberg maintains a Neutral rating on Quest Diagnostics and raises the price target from $145 to $150.
The raised price target from $145 to $150 suggests a positive outlook on Quest Diagnostics' future performance, which could lead to a short-term increase in stock price. However, the Neutral rating indicates that the analyst does not see significant upside potential beyond the new target.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100